Journal
NATURE REVIEWS DRUG DISCOVERY
Volume 6, Issue 9, Pages 734-745Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrd2380
Keywords
-
Ask authors/readers for more resources
Sunitinib malate (SU11248/ Sutent; Pfizer) is a multitargeted tyrosine kinase inhibitor that has potent anti-angiogenic and antitumour activities. Definitive efficacy has been demonstrated in advanced renal cell carcinoma and in gastrointestinal stromal tumours that are refractory or intolerant to imatinib (Gleevec; Novartis), which has provided the basis for the recent regulatory approvals for these indications. This article summarizes the discovery and development of sunitinib, and discusses key issues for the multitargeted approach in cancer treatment, such as markers of response and development of resistance, and their significance for the future development of sunitinib and other multikinase inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available